Irreversible Electroporation + CD40 Agonism + TIGIT Blockade Improves Outcomes in Aggressive Orthotopic PDAC Model

Clicks: 1
ID: 315778
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #320 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is an immunologically “cold” tumor with limited benefit from immune checkpoint inhibition. Irreversible electroporation (IRE) is a non-thermal local ablation therapy used in selected patients with advanced PDAC. In syngeneic orthotopic models, IRE plus intratumoral (IT) CD40 agonist antibody (CD40 Ab) showed anti-tumor immune effects and reduced liver metastases; this regimen is currently under clinical evaluation. TIGIT is an immune checkpoint that is highly co-expressed with PD-1 on infiltrating T cells in PDAC after IRE. Aims To evaluate whether systemic adjuvant TIGIT blockade (anti-TIGIT) improves outcomes after IRE+CD40 Ab in an aggressive orthotopic PDAC model. Methods Spontaneously metastasizing KPC46 PDAC organoids were implanted into the pancreatic tail of mice via laparotomy. When tumors reached approximately 7 mm, mice were randomized to sham laparotomy, IRE, IRE+CD40 Ab, sham+anti-TIGIT, IRE+anti-TIGIT, or IRE+CD40 Ab+anti-TIGIT (n=8-10/group). Immediately after IRE, CD40 Ab (50 µg) was administered IT once. Anti-TIGIT Ab (100 µg) was administered intraperitoneally every other day starting 48 hours post-IRE. Mice were euthanized on day 12 for assessment of tumor burden and immune profiling by flow cytometry. Survival cohorts included sham laparotomy, IRE, IRE+CD40 Ab, and IRE+CD40 Ab+anti-TIGIT. Results All IRE-treated groups showed smaller primary tumor volumes versus sham, with the greatest reduction after IRE+CD40 Ab+anti-TIGIT (Figure 1A). Flow cytometry demonstrated the largest reduction in regulatory T cells and the greatest increase in natural killer cells with triple therapy (not shown). These immune changes were associated with reduction in liver metastases on day 12 (Figure 1B). IRE+CD40 Ab+anti-TIGIT also improved survival over other groups with 22% complete responders (Figure 1C). Conclusion Adding systemic anti-TIGIT Ab to IRE+CD40 Ab improves local control, remodels the tumor immune microenvironment, reduces liver metastases, and prolongs survival. Ongoing experiments include rechallenging tumor-free surviving mice and comparison of anti-TIGIT to other immune checkpoint strategies.For image description, please refer to the figure legend and surrounding text.
Reference Key
openalex_W7163392483 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors H L Gros, H Sonowal, M Allsberry, L S Bohall, M Abou Assali, R White
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag055.008
URL
https://doi.org/10.1093/bjs/znag055.008
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.